Cellular senescence throws new insights into patient classification and pharmacological interventions for clinical management of hepatocellular carcinoma

Figure 6 Definition and external verification of a cellular-senescence-relevant gene signature. A: Cross-validation for tuning the parameter selection in the least absolute shrinkage and selection operator (LASSO) analysis in TCGA-LIHC dataset; B: LASSO coefficient profiling; C: Distribution of RiskScore, survival status, and transcript levels of genes in the signature; D: Kaplan–Meier (curves of overall survival in low- and high-RiskScore hepatocellular carcinomas; E: Receiver operator characteristic curves (ROCs) at 1-, 3- and 5-year survival; F: External verification of distribution of RiskScore, survival status, and transcript levels of genes in the International Cancer Genome Consortium (ICGC) dataset; G: Kaplan–Meier curves of overall survival in two groups in the ICGC dataset; H: ROCs at 1- and 3-year survival based upon RiskScore in the ICGC dataset; I: External validation of distribution of RiskScore, survival status, and transcript levels of genes in the GSE14520 dataset; J: Kaplan–Meier curves of overall survival in two groups in the GSE14520 dataset; K: ROCs at 1- and 3-year survival in the GSE14520 dataset.